| Bioactivity | Pegvorhyaluronidase alfa (PEGPH20) is a novel PEGylated recombinant human hyaluronidase. Pegvorhyaluronidase alfa is developed as an anticancer therapy for use in combination with other systemic therapies to facilitate their delivery to the tumor microenvironment (TME). Pegvorhyaluronidase alfa degrades tumor hyaluronan, thereby remodeling the TME[1]. |
| Name | Pegvorhyaluronidase alfa |
| CAS | 1620390-06-8 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eric Van Cutsem, et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020 Sep 20;38(27):3185-3194. |